475
Participants
Start Date
January 6, 2016
Primary Completion Date
September 25, 2017
Study Completion Date
June 5, 2019
Placebo
placebo via subcutaneous injection
Erenumab
erenumab via subcutaneous injection
Erenumab
erenumab via autoinjector (AI)/pen
Research Site, Kamogawa-shi
Research Site, Saijo-shi
Research Site, Ota-shi
Research Site, Hiroshima
Research Site, Sapporo
Research Site, Sapporo
Research Site, Sapporo
Research Site, Kobe
Research Site, Tsukuba
Research Site, Kahoku-gun
Research Site, Morioka
Research Site, Kagoshima
Research Site, Kawasaki-shi
Research Site, Kawasaki-shi
Research Site, Kawasaki-shi
Research Site, Kumamoto
Research Site, Kumamoto
Research Site, Kyoto
Research Site, Sendai
Research Site, Osaka
Research Site, Osakasayama-shi
Research Site, Toyonaka-shi
Research Site, Saga
Research Site, Iruma-gun
Research Site, Saitama-shi
Research Site, Tokorozawa-shi
Research Site, Shizuoka
Research Site, Shimotsuga-gun
Research Site, Bunkyo-ku
Research Site, Bunkyo-ku
Research Site, Chofu-shi
Research Site, Chuo-ku
Research Site, Hachioji-shi
Research Site, Minato-ku
Research Site, Minato-ku
Research Site, Shibuya-ku
Research Site, Shinjuku-ku
Research Site, Shinjuku-ku
Research Site, Yonago
Research Site, Toyama
Research Site, Toyama
Research Site, Hofu-shi
Research Site, Yamaguchi
Research Site, Kai-shi
Lead Sponsor
Amgen
INDUSTRY